Civica Long-Acting Insulin Available on January 1, 2026
Nearly 3 years ago, Breakthrough T1D joined forces with Civica Rx, a non-profit pharmaceutical company, to manufacture and distribute low-cost insulins. Starting on January 1, 2026, the first of those insulins, insulin glargine-yfgn (a long-acting insulin interchangeable with Lantus®), will be available for purchase. 5 Pens, No More Than $55 – for anyone While we […]
The Nobel Prize goes to… Immunologists (with a Breakthrough T1D connection!)
The Nobel Prize in Physiology or Medicine went to three immunologists, including one, Fred Ramsdell, who founded a T1D Fund company.
The inside scoop on the CATT1 clinical trial
Learn about the people making the CATT1 clinical trial happen, the science behind cadisegliatin for type 1 diabetes, and how to get involved.
Special Diabetes Program yields $50+ billion in Federal healthcare savings
Analysis compiled by Avalere Health and supported by Breakthrough T1D (formerly JDRF) finds that research funded by the Special Diabetes Program (SDP) has yielded more than $50 billion in federal healthcare savings. Created by Congress in 1997 and administered by the National Institutes of Health (NIH), the SDP provides federal funding to support research to prevent, treat, and […]
Research updates from EASD 2025
There is always breaking, inspiring news in the world of type 1 diabetes (T1D) research—and that news was front and center at the 2025 European Association for the Study of Diabetes (EASD) Meeting. This annual event is one of the largest diabetes conferences in the world, and Breakthrough T1D staff, partners, funded researchers, and more […]
Study: Patients willing to incur risks for benefits of novel T1D therapies
A new Breakthrough T1D-funded study finds that people with T1D and their caregivers are largely willing to try advanced new T1D therapies.
Hy-Vee and Breakthrough T1D: Changing lives
Hy-Vee has been a trusted partner of Breakthrough T1D since 1988, raising nearly $20 million through corporate and store events.
A new Breakthrough T1D publication is paving the way for beta cell replacement therapies
Breakthrough T1D’s newest publication outlines a roadmap for beta cell replacement therapies for type 1 diabetes.
New publication alert: Engineered islets are making insulin and avoiding immune detection in first person treated
Hypoimmune (HIP) islets are making insulin, without immunosuppressants, in the first person treated with type 1 diabetes.
“We are our own solution:” A T1D parent’s reflection on progress
Moira McCarthy reflects on the transformative impact of automated insulin delivery systems, and how the T1D community made it possible.
